NICE does not recommend Roche's Ocrevus for MS

The U.K.'s NICE published draft guidance recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat relapsing forms of multiple sclerosis.

The committee said the clinical trial data that Roche submitted did not directly compare Ocrevus with other treatments. The committee also found that MS therapy Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) was more effective and less costly than Ocrevus in almost all of its analyses, both in the whole population and in the highly active and rapidly evolving severe subgroups, and concluded that Ocrevus was not cost effective compared with Lemtrada...